The mechanism is that ALKBH5 affects the efficacy of immunotherapy during immune checkpoint blockade by regulating the expression and lactate content of MCT4/Slc16a3 in TME and the composition of tumor-infiltrating T cells and myeloid suppressor cells. Here, ALKBH5 is linked to neoplasm.